Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics ($APGE), made 29 open market sales of company shares over the last year, totaling $4.8 million. His most recent sale occurred on March 4, 2026. These activities rank 1,992nd among 11,678 insiders in the database, trailing the average of $8.6 million sold and 6.4 transactions per insider. Dambkowski recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 200 | $73.26 | 209,773.0000 | 68,320,229 | 0.10% | 0.00% |
| March 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 4125 | $0.00 | 131,290.0000 | 68,320,229 | 3.05% | 0.01% |
| March 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 4125 | $22.86 | 215,273.0000 | 68,320,229 | 1.95% | 0.01% |
| March 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 3225 | $70.33 | 212,048.0000 | 68,320,229 | 1.50% | 0.00% |
| March 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2075 | $71.98 | 209,973.0000 | 68,320,229 | 0.98% | 0.00% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2481 | $64.88 | 214,167.0000 | 68,320,229 | 1.15% | 0.00% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 4125 | $22.86 | 216,648.0000 | 68,320,229 | 1.94% | 0.01% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 4125 | $0.00 | 135,415.0000 | 68,320,229 | 2.96% | 0.01% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 200 | $68.94 | 211,148.0000 | 68,320,229 | 0.09% | 0.00% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 100 | $67.88 | 211,348.0000 | 68,320,229 | 0.05% | 0.00% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 1299 | $66.85 | 211,448.0000 | 68,320,229 | 0.61% | 0.00% |
| Feb. 4, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 1420 | $65.83 | 212,747.0000 | 68,320,229 | 0.66% | 0.00% |
| Jan. 23, 2026 | Oruka Therapeutics, Inc. | $ORKA | Dambkowski Carl | Director | J | Common Stock | 116483 | $0.00 | 116,483.0000 | 42,095,951 | 9999.99% | 0.28% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 14025 | $22.86 | 231,223.0000 | 68,320,229 | 6.46% | 0.02% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 14820 | $77.90 | 213,449.0000 | 68,320,229 | 6.49% | 0.02% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 14025 | $0.00 | 139,540.0000 | 68,320,229 | 9.13% | 0.02% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2954 | $77.13 | 228,269.0000 | 68,320,229 | 1.28% | 0.00% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 826 | $79.04 | 212,623.0000 | 68,320,229 | 0.39% | 0.00% |
| Jan. 7, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 100 | $80.06 | 212,523.0000 | 68,320,229 | 0.05% | 0.00% |
| Jan. 2, 2026 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | A | Stock Option (Right to Buy) | 83690 | $0.00 | 83,690.0000 | 68,320,229 | 9999.99% | 0.12% |
| Dec. 4, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 10900 | $75.00 | 271,108.0000 | 68,320,229 | 3.87% | 0.02% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2200 | $54.83 | 288,293.0000 | 68,320,229 | 0.76% | 0.00% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 8060 | $22.86 | 292,793.0000 | 68,320,229 | 2.83% | 0.01% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 8060 | $0.00 | 153,565.0000 | 68,320,229 | 4.99% | 0.01% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 678 | $56.51 | 282,008.0000 | 68,320,229 | 0.24% | 0.00% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 5607 | $55.58 | 282,686.0000 | 68,320,229 | 1.94% | 0.01% |
| Nov. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2300 | $53.62 | 290,493.0000 | 68,320,229 | 0.79% | 0.00% |
| Oct. 1, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 5110 | $39.80 | 284,733.0000 | 46,016,542 | 1.76% | 0.01% |
| Oct. 1, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 2385 | $22.86 | 289,843.0000 | 46,016,542 | 0.83% | 0.01% |
| Oct. 1, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 2385 | $0.00 | 161,625.0000 | 46,016,542 | 1.45% | 0.01% |
| Sept. 3, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2535 | $37.82 | 233,738.0000 | 46,016,542 | 1.07% | 0.01% |
| Sept. 3, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 190 | $38.55 | 233,548.0000 | 46,016,542 | 0.08% | 0.00% |
| Aug. 6, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2725 | $37.78 | 236,273.0000 | 46,016,542 | 1.14% | 0.01% |
| July 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 6409 | $44.77 | 242,679.0000 | 46,016,542 | 2.57% | 0.01% |
| July 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 7365 | $0.00 | 164,010.0000 | 46,016,542 | 4.30% | 0.02% |
| July 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 746 | $46.26 | 238,998.0000 | 46,016,542 | 0.31% | 0.00% |
| July 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2935 | $45.49 | 239,744.0000 | 46,016,542 | 1.21% | 0.01% |
| July 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 7365 | $22.86 | 249,088.0000 | 46,016,542 | 3.05% | 0.02% |
| June 4, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2725 | $36.96 | 241,723.0000 | 46,016,542 | 1.11% | 0.01% |
| June 2, 2025 | Oruka Therapeutics, Inc. | $ORKA | Dambkowski Carl | Director | A | Stock Option (right to buy) | 17500 | $0.00 | 17,500.0000 | 41,679,560 | 9999.99% | 0.04% |
| May 7, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2725 | $35.75 | 244,448.0000 | 46,016,542 | 1.10% | 0.01% |
| April 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2471 | $35.56 | 248,562.0000 | 46,016,542 | 0.98% | 0.01% |
| April 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 500 | $37.03 | 248,062.0000 | 46,016,542 | 0.20% | 0.00% |
| April 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 889 | $37.59 | 247,173.0000 | 46,016,542 | 0.36% | 0.00% |
| March 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 1590 | $30.48 | 251,033.0000 | 46,016,542 | 0.63% | 0.00% |
| Feb. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 795 | $22.86 | 256,143.0000 | 0 | 0.31% | 0.00% |
| Feb. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 3520 | $40.69 | 252,623.0000 | 0 | 1.37% | 0.00% |
| Feb. 5, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 795 | $0.00 | 171,375.0000 | 0 | 0.46% | 0.00% |
| Jan. 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 1360 | $0.00 | 172,170.0000 | 0 | 0.78% | 0.00% |
| Jan. 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 100 | $47.92 | 255,348.0000 | 0 | 0.04% | 0.00% |
| Jan. 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 1360 | $22.86 | 259,433.0000 | 0 | 0.53% | 0.00% |
| Jan. 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 1499 | $46.42 | 257,934.0000 | 0 | 0.58% | 0.00% |
| Jan. 2, 2025 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2486 | $47.21 | 255,448.0000 | 0 | 0.96% | 0.00% |
| Dec. 11, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 455 | $50.00 | 258,073.0000 | 0 | 0.18% | 0.00% |
| Dec. 11, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Common Stock | 1815 | $22.86 | 262,613.0000 | 0 | 0.70% | 0.00% |
| Dec. 11, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 4085 | $48.62 | 258,528.0000 | 0 | 1.56% | 0.00% |
| Dec. 11, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | M | Stock Option (Right to Buy) | 1815 | $0.00 | 173,530.0000 | 0 | 1.04% | 0.00% |
| Dec. 9, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | A | Stock Option (Right to Buy) | 124962 | $0.00 | 124,962.0000 | 0 | 9999.99% | 0.00% |
| Dec. 4, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 6665 | $46.07 | 260,798.0000 | 0 | 2.49% | 0.00% |
| Nov. 6, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 5326 | $58.91 | 268,802.0000 | 0 | 1.94% | 0.00% |
| Nov. 6, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 1339 | $59.96 | 267,463.0000 | 0 | 0.50% | 0.00% |
| Oct. 2, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 5740 | $56.16 | 275,053.0000 | 0 | 2.04% | 0.00% |
| Oct. 2, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 925 | $56.86 | 274,128.0000 | 0 | 0.34% | 0.00% |
| Sept. 4, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 787 | $48.06 | 280,793.0000 | 0 | 0.28% | 0.00% |
| Sept. 4, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 5878 | $47.49 | 281,580.0000 | 0 | 2.04% | 0.00% |
| Aug. 7, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 6523 | $40.47 | 288,270.0000 | 0 | 2.21% | 0.00% |
| Aug. 7, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 670 | $42.56 | 287,458.0000 | 0 | 0.23% | 0.00% |
| Aug. 7, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 142 | $41.09 | 288,128.0000 | 0 | 0.05% | 0.00% |
| July 3, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 3852 | $37.29 | 296,936.0000 | 0 | 1.28% | 0.00% |
| July 3, 2024 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | S | Common Stock | 2143 | $38.16 | 294,793.0000 | 0 | 0.72% | 0.00% |
| Dec. 18, 2023 | Apogee Therapeutics, Inc. | $APGE | Dambkowski Carl | Chief Medical Officer | A | Stock Option (Right to Buy) | 175345 | $0.00 | 175,345.0000 | 0 | 9999.99% | 0.00% |